tbuckley/cabot-search huggingface dataset:
POS1358 BURDEN OF OSTEOARTHRITIS IN CHINA FROM 1990 TO 2019 AND PREDICTIONS OF THE BURDEN IN FUTURE 25 YEARS: FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY 2019
Authors: H. Chen, Z. Zhou, X. Fang, D. Hunter, C. Ding, Z. Zhu
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> China has the world's largest population and a high prevalence of osteoarthritis (OA), accompanying by a rapidly ageing and increasingly obese population <sup>[1-2]</sup>. However, the disease burden and secular trend of OA in China have not been well described nor predicted. <h3>Objectives</h3> To describe and predict the epidemiological features and secular trends attributable to OA in China from 1990 to 2044 in a comprehensive manner. <h3>Methods</h3> Data from the Global Burden of Disease (GBD) Study 2019 were used to estimate the incidence, prevalence, disability-adjusted life years (DALYs) and the related age-standardized rates (ASRs) of OA, as well as the burden of OA due to a high body mass index (BMI). The estimated annual percentage change (EAPC) in the ASRs was used to describe the temporal trend of OA changes and the Norpred age-period-cohort (APC) model was used to predict the disease burden over the next 25 years. <h3>Results</h3> The prevalence of OA in China increased from 51.76 (45.95-58.26) million in 1990 to 132.81 (118.00-149.08) million in 2019. The ASR of OA incidence increased from 472.53/100,000 in 1990 to 509.84/100,000 in 2019, with an EAPC of 0.36 (0.29-0.44); the ASR of OA prevalence increased from 5880.58/100,000 in 1990 to 6330.06/100,000 in 2019, with an EAPC of 0.35 (0.28-0.42), and the ASR of OA DALYs increased from 206.38/100,000 in 1990 to 224.78/100,000 in 2019, with an EAPC of 0.40 (0.32-0.48). The ASR of OA DALYs associated with high BMI increased rapidly from 1990 to 2019, especially in male and hip OA (Table 1). The projections suggested that there will be an increasing trend in the incidence (male 27.92%; female 15.51%), prevalence (male 71.08%; female 50.30%) and DALYs (male 71.93%; female 50.02%) of OA from 2020 to 2044, and the prevalence and DALYs of OA in China would increase by approximately 1.5 times in future 25 years. (Figure 1). <h3>Conclusion</h3> The disease burden of OA has increased in China in the past 30 years and will continue to rise over the next 25 years. Therefore, prevention and early intervention are pivotal to mitigating the growing burden of OA. <h3>References</h3> [1]Long H, Liu Q, et al. Arthritis Rheumatol. 2022 [2]Wang L, Zhou B, et al. Lancet. 2021 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0595 TESTING A NEW FATIGUE CHECKLIST IN SLE PATIENTS FOR EVERYDAY CLINICAL PRACTICE - AN INTERIM ANALYSIS
Authors: C. Duesing, J. Richter, C. Elling-Audersch, D. Fell, M. Schmid-Holl, O. Sander, J. Mucke, I. Haase, R. Fischer-Betz, H. Acar, T. Filla, M. Schneider, G. Chehab
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Fatigue is a difficult subject for both physicians and patients. It is barely addressed during consultations and can therefore burden patient-physician-relations. To improve communication regarding fatigue, we developed a checklist that includes suggestions for evaluating possible causes for fatigue. In this analysis, we describe our study population and report first results 3 and 6 months after using the checklist. <h3>Objectives</h3> The aims of our study are to validate the use of our newly developed fatigue checklist and to demonstrate that addressing fatigue in daily clinical practice and offering possible interventions can improve fatigue. <h3>Methods</h3> We recruited n=110 SLE patients with fatigue from our university hospital-based lupus reference centre in Duesseldorf. Fatigue was measured using the FSS (Fatigue Severity Scale). Our checklist included signs of depression and anxiety using the PHQ-4 (Patient Health Questionnaire), BMI (body mass index), physical activity, anemia, hypothyroidism and vitamin D deficiency. For each applicable cause, we listed possible interventions for free selection by the treating physician, such as replacement therapy (vitamin D, vitamin B12, iron, folic acid, erythropoietin), physical activity programs and psychosomatic consultations that were discussed with the patients. We re-evaluated our patients after 3 (T1) and 6 months (T2). <h3>Results</h3> Baseline characteristics of patients are summarized in Table 1. After 3 and 6 months, we re-evaluated 83 patients and saw a significant reduction in fatigue measured by the FSS score (T1: mean difference estimate 0.367 and p-value &lt;0.001; T2: mean difference estimate 0.305; p-value &lt;0.005). <h3>Conclusion</h3> The preliminary analysis of our study shows for the first time that incorporation of a checklist procedure into the management of patients with fatigue may improve short-term outcome after 3 and 6 months of observation. The improvement of symptoms documented in our study occurred even though the suggested exercise program and psychosomatic counseling sessions were not available for use during the current observation period because of the COVID-19 pandemic. At present, the mechanisms behind the observed effect remain unclear. Our ongoing analysis will clarify whether an additional effect on fatigue will occur after all suggested interventions resulting from the use of the checklist have been executed. Finally, it will demonstrate whether the incorporation of our checklist into routine clinical practice is capable to reduce fatigue over a prolonged time period. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
Age-related physical health of older autistic adults in Sweden: a longitudinal, retrospective, population-based cohort study
Authors: Shengxin Liu, Henrik Larsson, Ralf Kuja-Halkola, Paul Lichtenstein, Agnieszka Butwicka, Mark J Taylor
Journal: The Lancet Healthy Longevity (2023)

Research of health outcomes in older autistic adults (≥45 years) is concerningly scarce, and little is known about whether intellectual disability and sex affect the health outcomes of this population. The aim of this study was to investigate the association between autism and physical health conditions in older adults and to examine these associations by intellectual disability and sex.
AB1837-HPR THE NON-INFLAMMATORY RHEUMATIC DISEASES AND CARDIOVASCULAR RISK: THE UNKNOWN COMORBIDITY
Authors: Y. Mabrouk, H. Ferjani, H. Riahi, D. Ben Necib, E. Labben, D. Kaffel, K. Maatallah, M. Bouaziz, W. Hamdi
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Several factors were associated with non-inflammatory rheumatic diseases such as diabetes and overweight. As far as we know, no previous research has studied cardiovascular risk in this population. For this goal, we used the carotid intima-media thickness (cIMT) screening as a relevant tool for CV risk assessment. <h3>Objectives</h3> This study mainly aimed to determine the importance of CV risk in non-inflammatory rheumatic diseases. <h3>Methods</h3> The present study is a study conducted on Tunisian non-inflammatory rheumatism patients in the rheumatology department. We collected the characteristics of the patients and those of the disease. The CV risk was assessed using the measurement of cIMT. According to the American Society of Echocardiography guidelines, the cIMT thickness was measured using high-resolution B-mode carotid US with a Philips machine with the patient in the supine position. The cIMT was measured using the two inner layers of the common carotid artery and an increased IMT was defined as ≥0.09 cm. <h3>Results</h3> Fifty patients were collected, of which 82% were women. 64% of them were followed for knee osteoarthritis, the rest were chronic low back pain patients. The mean age was 53 ± 11.08 years. 10% of patients were active smokers. Two percent were hypertensive and 4% were diabetics. The average BMI was 28,1±4,5 kg/m2. It was greater than 25 kg/m2 in 76% of them. [cholesterol] was 4,9±0,9 mmol/l. 48,9% had a high rate. [Cholesterol HDL] was1,1±0,2 mmol/l. The mean [cholesterol LDL] was 3,3 ±0,8 mmol/l. [triglyceride] was 1,3±0,6 mmol/l. The mean IMT in the left common carotid (LCC) was 0,06±0,02, in the left internal carotid (LIC) was 0,06±0,01, in the left external carotid (LEC) was 0,05±0,01. The mean IMT was 0,05±0,018 in the right common carotid (RCC), 0,06±0,01 in the right internal carotid (RIC), and 0,05±0,01 in the right external carotid (REC). Thirty six percent had an atheroma plaque. Twenty six percent had a high CV risk according to the IMT. There was no correlation in our series between diabetes, high blood pressure, smoking, BMI, and high CV risk p=1; p=1; p=1, and p=0.5, respectively. <h3>Conclusion</h3> While the absence of systemic inflammation in non-inflammatory osteoarticular diseases, the cardiovascular risk is higher in our study. Therefore, cardiovascular risk screening should not be limited to chronic inflammatory rheumatism. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0347 PREDICTIVE FACTORS OF SLEEP DISORDERS IN RHEUMATOID ARTHRITIS PATIENTS: A CROSS-SECTIONAL STUDY
Authors: M. Brahem, S. Abdellatif, B. Jebali, R. Sarraj, A. Ben Salem, O. Joma, H. Hachfi, Y. Mohamed
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Rheumatoid Arthritis (RA) is a chronic inflammatory disease that causes chronic inflammatory joint pain that disturbs the quality of life of patients including sleep disorders. <h3>Objectives</h3> The aim of our study was to evaluate the quality of sleep of RA patients and to determine the predictive factors of sleep disturbance. <h3>Methods</h3> This is a cross-sectional study conducted among patients followed in the rheumatology department for RA. All patients were diagnosed with RA based on ACR/EULAR criteria. We assessed them for sleep disorders using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) after clear consent. <h3>Results</h3> One hundred patients (11 men (11%) and 89 women (89%)) were included. The average age was 53.2 ±11.21 years. The mean duration of the disease was 11.1 years [1 - 40 years]. 70% of the participants had joint deformities,35% had extra-articular manifestations and 17% were obese. 81% of patients were treated with Methotrexate and 10% received biological treatment. The mean visual analogic scale (VAS) was 5.19/10 [1-9] and the average Swollen joints count (SJC) and Tender joints count (TJC) were consecutively 8.5 et 3,95 [0-24]. The average DAS28(CRP) score was 4.6±1,19 and DAS28(ESR) was 3,8±1,19. The mean ESR and CRP values were 46 mm at the first hour and 14.7 mg/L respectively. The disease was very active (DAS 28 ≥ 5.1) in 34% of patients. The average HAQ (Health Assessment Questionnaire) was 1.28±0.7. The mean Epworth score was 7.9 with extremes ranging from 0 to 24. The majority of our population (72%) had normal daytime sleepiness (ESS≤10) and 28% had excessive daytime sleepiness (ESS ≥11). The mean PSQI score was 6,9 [0-19]. Almost half of our RA patients had sleep disorders with an index of PSQI≥5.5. Statistical analysis found a positive significant correlation between the ESS score and the VAS, TJC, SJC, DAS28, HAQ scales, and female gender. Also, we proved a significant relationship between sleep disorders based on the PSQI scale and higher DAS28 (p&lt;0.01), TJC (&lt;0.01), SJC (&lt;0.01), CRP (p&lt;0.01), VAS (p&lt;0.05), and HAQ (p&lt;0.01). Based on the multivariate study, a high CRP and SJC were found to be predictive factors to sleep disorders according to the PSQI score. on the other hand, the presence of extra-articular manifestations, female gender, and higher VAS were considered as predictive factors of this disorder in conformity with the Epworth score. <h3>Conclusion</h3> Sleep disorders are common among RA patients and they were essentially related to disease activity and functional disability, so it is important to guarantee the remission or low disease activity to improve sleep quality in these patients. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0562 BELIMUMAB FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN REAL WORLD: A SINGLE CENTER STUDY
Authors: J. J. Fragío Gil, P. Martinez Calabuig, L. Salvador Maicas, R. González Mazarío, A. Rueda, J. J. Lerma, C. Molina Almela, M. D. Pastor Cubillo, C. Campos Fernández
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Belimumab efficacy and safety has been studied through randomized controlled trials in Systemic Lupus Erythematosus (SLE) patients even in cases with kidney involvement. However, more evidence is needed not only from long-term trials but also from real world conditions especially in Lupus Nephritis (LN) patients. <h3>Objectives</h3> To analyze the effectiveness and safety of Belimumab in SLE patients with data from a Real-World cohort. <h3>Methods</h3> A single center observational study was performed including SLE patients who had initiated treatment with Belimumab from September 2017 to January 2023. Demographic, clinical, laboratory, effectiveness and safety variables were collected. Effectiveness was evaluated according to changes from the baseline in SLEDAI-2K and disease activity markers (proteinuria, complement consumption and/or Anti DNAds). Safety data was collected including any adverse event (AE) due to any cause. AE was considered serious (SAE) if it was life-threatening or result in hospitalization, disability or in death. <h3>Results</h3> Overall, 15 patients were included in the study, whom baseline characteristics are exposed in the Table 1. Nine patients were still receiving the drug with a mean drug survival of 15.6 months. Belimumab allowed steroid tapering in all cases, but treatment was discontinued just in 1 patient (7%). Treatment also improved disease activity markers in all (100%) patients. Belimumab was well tolerated, and the AE reported were infection (14 events) and malaise in 1 patient. In 11 cases, infection was mild (9 upper respiratory tract infection, 1 urinary tract infection and 1 gastroenteritis). 3 severe infections were registered (1 pneumonia, 1 pyelonephritis and 1 meningitis). Regarding LN patients, treatment exposure achieved was 10.85 patients/year. Renal Biopsy demonstrated class III in a patient (20%) and class IV in 4 patients (80%). Mean proteinuria at baseline was 6.66g/24h. In 3 cases, Belimumab was started in the first 6 months after LN diagnosis was established. In 4 cases (80%), Belimumab addition allowed significant reduction of proteinuria and corticosteroids. In 2 out 5 (40%) treatment was discontinued, one case due to an insufficient response and in the other, to a SAE (<i>Cryptococcus neoformans</i> meningitis). <h3>Conclusion</h3> Belimumab maintained an acceptable safety profile and an adequate effectiveness. Intravenous and subcutaneous formulations showed similar performance. Belimumab addition resulted in reduction in proteinuria and corticosteroid use. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0932 LONG-TERM CORTICOSTEROID THERAPY WAS ASSOCIATED WITH SIGNIFICANT LIVER FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS
Authors: G. Cuomo, C. Iandoli, C. Di Vico, D. Perretta, R. Ferrara, L. Rinaldi, R. Galiero, A. Caturano, F. C. Sasso
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Fibrotic changes of the internal organs, such as lungs, heart, kidneys, and gastrointestinal tract, characterize the clinical course of both limited (lcSSc) and diffuse cutaneous SSc (dcSSc), potentially leading to organ dysfunction. However, liver involvement is less defined. <h3>Objectives</h3> In a cross-sectional study we investigated the prevalence and predictors of significant liver fibrosis in patients with systemic sclerosis (SSc) who had no evidence of liver diseases due to heavy alcohol consumption, viral infection, drug. <h3>Methods</h3> A total of 65 SSc patients were recruited, satisfied the 2013 ACR)/ (EULAR) classification. In addition to the clinical and laboratory data, modified Rodnan skin score (mRSS), and activity index, video-capillaroscopy, echocardiography, and lung function were analysed. Liver stiffness (LS) was measured using transient elastography to assess the degree of liver fibrosis and 7.4 kPa was adopted as the cut-off value for significant liver fibrosis and liver steatosis with CAP values ≥ 248 dB/m were considered consistent with mild steatosis (S1), ≥268 dB/m with moderate steatosis (S2) and ≥280 dB/m with severe steatosis (s3) <h3>Results</h3> The median age of patients (60 women) was 50.5 years (range 20-80) and the median disease duration was 5.5 years (range 1-10). The median LS value was 4.65 kPa (range 3.1-8.3); the median CAP value was 220.5 (164-327). By Spearman Rank Correlation LS value vs age has a p value 0.02 (CI 95% 0.290.64), vs corticosteroid use has a p value 0.0032 (CI95% 0.179-0.731). On the contrary Cap value vs age has a p value 0.026 (CI 95% 0.04-0.64). Forty-six (70.8%) patients had no fibrosis (F=0); 17 (26%) had a LS value from 5.2 and 7.4; 3 patient (4.6%) LS&gt;7.4 (F3) significant liver fibrosis. Eight patients (12.3%) had mild liver steatosis (CAP value was ≥ 248 dB/m) and 6 patient (9.2%) had moderate steatosis (S2) (CAP value ≥268 dB/m) <h3>Conclusion</h3> In our study <b>t</b>he prevalence of significant liver fibrosis was relatively low (4.6%). Long-term corticosteroid therapy was associated with increased liver stiffness on Fibroscan. T<b>he</b> low number of patients is a limitation of the study, we await the data relating to a more representative population. <h3>Reference</h3> [1]Maria Lorena et al;. J. Clin. Med. 2022 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0625 THE ATTRIBUTION OF NEUROPSYCHIATRIC EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: DATA FROM “ATTIKON” LUPUS COHORT
Authors: D. Nikolopoulos, N. Kapsala, O. Gioti, S. Flouda, A. Pieta, K. Chavatza, T. Karageorgas, D. Tseronis, P. Katsimbri, D. Boumpas, A. Fanouriakis
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The attribution of neuropsychiatric manifestations to systemic lupus erythematosus (SLE) or unrelated causes is often obscure. <h3>Objectives</h3> The attribution of neuropsychiatric events to lupus (SLE related) or other causes (non-SLE related) in a large SLE cohort. <h3>Methods</h3> Retrospective study of 707 SLE patients from "Attikon" lupus cohort <sup>[1,2]</sup>. Neuropsychiatric manifestations were classified as either primary neuropsychiatric SLE (SLE related; attributed to SLE using a combination of multidisciplinary physician judgment with attribution models <sup>[3]</sup>) or secondary NPSLE (non-SLE related; neuropsychiatric manifestations not attributed to SLE) or manifestations of uncertain attribution. <h3>Results</h3> 258 patients developed 345 NP events in total. Among them, 140 (40.6%) were attributed to SLE, while 148 (42.9%) were classified as secondary NPSLE. In 57 NP events, the attribution remained uncertain. Among primary NP manifestations, cerebrovascular events (n=34, 24.3%), seizures (n=25, 17.8%) and cranial neuropathies (n=18, 5.2%) were the most common, while mood disorders (n=69, 46.6%) and headache (n=22, 14.9%) were the most common secondary NPSLE. The extra-CNS clinical and serological phenotype do not differ between primary and secondary NPSLE. Patients with primary NPSLE as compared to secondary NPSLE, were more likely to accrue irreversible damage (SLICC damage index &gt; 0) (OR=2.88, 95%CI 1.67-4.96) and develop additional neuropsychiatric manifestations (OR=3.74, 95%CI 1.98-7.09). <h3>Conclusion</h3> A significant proportion of NP events cannot classified as primary or secondary NPSLE. Cerebrovascular eventσ and seizures are the most common primary NP manifestations in SLE. The primary NPSLE is associated with accrual of irreversible damage and increased risk of developing additional NP manifestations. <h3>References</h3> [1]Nikolopoulos D, Kostopoulou M, Pieta A, Karageorgas T, Tseronis D, Chavatza K. Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the ' Attikon ' cohort. Lupus. 2020:1-9. doi:10.1177/0961203320908932 [2]Nikolopoulos D, Kitsos D, Papathanasiou M, et al. Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the "Attikon" Lupus Cohort. Front Neurol. 2022;13. doi:10.3389/FNEUR.2022.889613 [3]Bortoluzzi A, Scirè CA, Bombardieri S, et al. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology. 2014;54(5):891-898. doi:10.1093/rheumatology/keu384 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1079 CLINICAL, RADIOLOGICAL AND BIOLOGICAL CHARACTERISTICS OF SPONDYLOARTHRITIS WITH COXITIS
Authors: H. Arabi, F. Idrissi Zaki, H. Tebaa, A. Mougui, I. El Bouchti
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Spondyloarthritis (SpA) is the most common chronic inflammatory rheumatic disease with hip involvement, which is a marker of disease severity, given its major functional impact. <h3>Objectives</h3> Determine the clinical, biological and radiological characteristics of SpA with coxitis, and to determine the factors associated with its occurrence. <h3>Methods</h3> Retrospective and analytic study including patients with SpA. Clinical demographics, biological radiological data, and activity scores were collected. The significance threshold was set for a value of p&lt;0.05. <h3>Results</h3> These were 333 patients, of which 54.1% were men. The mean age was 40.52±15.05 years, and the mean age at onset was 32.02±15.42. The percentage of smoking patients was 11.1%. HLA-B27 was positive in 57% and uveitis was present in 7.2% of patients. Coxitis was present in 25.52% of patients, it was inaugural in 10.5% and bilateral in 71.76% of cases. Coxitis was more common in men; the male gender accounted for 76.47% in SpA with coxitis versus 46.37% without coxitis (p&lt;0.001). The mean age of SpA onset was lower in patients who developed coxitis (24.4±13.75 years versus 34.6±15.14 years; p = 0.014). Pure axial form and low back and buttock pain were more noted in patients with coxitis (18.8% versus 13.3% p=0.022, 31.7% versus 18.9% p=0.018 respectively). Enthesopathy was more common in SpA without coxitis (56.86% versus 35.3%, p=0.001). There was no significant difference between the two groups for CRP and erythrocyte sedimentation rate (p=0.91; p=0.35), nor for ASDAS and BASDAI (p=0.95; p=0.38 respectively). Also a frequency not modified by the presence or absence of coxitis was noted, in particular for the family history of SpA, smoking, HLA-B27, uveitis, the existence of radiographic sacroilitis. In multivariate analysis, coxitis was associated with male gender, early age of onset, and pure axial form. <h3>Conclusion</h3> Our study showed that the presence of coxitis was associated with early disease onset, male sex and pure axial form of SpA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.